"Iodine Radioisotopes" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Unstable isotopes of iodine that decay or disintegrate emitting radiation. I atoms with atomic weights 117-139, except I 127, are radioactive iodine isotopes.
| Descriptor ID |
D007457
|
| MeSH Number(s) |
D01.268.380.400.500.496 D01.496.448.496 D01.496.749.474
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Iodine Radioisotopes".
Below are MeSH descriptors whose meaning is more specific than "Iodine Radioisotopes".
This graph shows the total number of publications written about "Iodine Radioisotopes" by people in this website by year, and whether "Iodine Radioisotopes" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 5 | 7 | 12 |
| 1995 | 1 | 2 | 3 |
| 1996 | 2 | 1 | 3 |
| 1997 | 3 | 0 | 3 |
| 1998 | 0 | 6 | 6 |
| 1999 | 4 | 5 | 9 |
| 2000 | 5 | 5 | 10 |
| 2001 | 2 | 5 | 7 |
| 2002 | 2 | 3 | 5 |
| 2003 | 4 | 8 | 12 |
| 2004 | 1 | 5 | 6 |
| 2005 | 2 | 5 | 7 |
| 2006 | 2 | 6 | 8 |
| 2007 | 3 | 8 | 11 |
| 2008 | 1 | 2 | 3 |
| 2009 | 4 | 4 | 8 |
| 2010 | 3 | 4 | 7 |
| 2011 | 5 | 3 | 8 |
| 2012 | 2 | 6 | 8 |
| 2013 | 0 | 1 | 1 |
| 2014 | 4 | 4 | 8 |
| 2015 | 3 | 7 | 10 |
| 2016 | 2 | 1 | 3 |
| 2017 | 3 | 2 | 5 |
| 2018 | 3 | 2 | 5 |
| 2019 | 1 | 5 | 6 |
| 2020 | 1 | 2 | 3 |
| 2021 | 3 | 6 | 9 |
| 2022 | 2 | 9 | 11 |
| 2023 | 1 | 4 | 5 |
| 2024 | 0 | 3 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Iodine Radioisotopes" by people in Profiles.
-
Thyroid Cancer: A Review. JAMA. 2024 02 06; 331(5):425-435.
-
Increased Progression-Free Survival with Cabozantinib Versus Placebo in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Irrespective of Prior Vascular Endothelial Growth Factor Receptor-Targeted Therapy and Tumor Histology: A Subgroup Analysis of the COSMIC-311 Study. Thyroid. 2024 Mar; 34(3):347-359.
-
Pralsetinib in Patients with Advanced/Metastatic Rearranged During Transfection (RET)-Altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW Study. Thyroid. 2024 01; 34(1):26-40.
-
Retrospective Analysis of Radiation-Induced Complications of Uveal Melanoma Patients Treated With Brachytherapy in the Era of Anti-VEGF. Am J Ophthalmol. 2024 Apr; 260:49-59.
-
Diagnosis and Management of Tropomyosin Receptor Kinase Fusion-Positive Thyroid Carcinomas: A Review. JAMA Oncol. 2023 08 01; 9(8):1132-1141.
-
Review article: new treatments for advanced differentiated thyroid cancers and potential mechanisms of drug resistance. Front Endocrinol (Lausanne). 2023; 14:1176731.
-
Outcomes after PD-103 versus I-125 for low dose rate prostate brachytherapy monotherapy: An international, multi-institutional study. Radiother Oncol. 2023 06; 183:109599.
-
Biomarker response to high-specific-activity I-131 meta-iodobenzylguanidine in pheochromocytoma/paraganglioma. Endocr Relat Cancer. 2023 02 01; 30(2).
-
Time to resolution of iodine-123 metaiodobenzylguanidine (123 I-MIBG) avidity and local control outcomes for high-risk neuroblastoma following radiation therapy. J Med Imaging Radiat Oncol. 2023 Feb; 67(1):81-88.
-
Cabozantinib for previously treated radioiodine-refractory differentiated thyroid cancer: Updated results from the phase 3 COSMIC-311 trial. Cancer. 2022 12 15; 128(24):4203-4212.